GlassScriptPhysician profile
Jennifer Hubbard
NPI 1962023218
$11,580.23
in general payments reported to CMS, 2019-2025
14 companies · $889 in 2025
The $889 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $110 · 2022: $443 · 2023: $5,982 · 2024: $4,156 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,075 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,740 · Travel and Lodging: $3,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,075.20 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,740.00 |
| Travel and Lodging | $3,211.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immedica Pharma US, INC. | $6,620.46 | 2023-2024 | |
| Livanova USA, INC. | $2,650.58 | 2023-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Jazz Pharmaceuticals INC. | $1,265.32 | 2022-2025 | |
| Ucb, INC. | $398.27 | 2022-2025 | Fintepla |
| Genentech, INC. | $163.08 | 2025 | Ocrevus |
| E.R. Squibb & Sons, L.L.C. | $105.28 | 2024 | Reblozyl |
| Sumitomo Pharma America, INC. | $75.80 | 2023 | Aptiom |
| Biocodex, INC. | $70.53 | 2025 | |
| Neurelis, INC. | $64.45 | 2023-2025 | Valtoco |
| Zogenix INC. | $60.04 | 2021 | |
| Sk Life Science, INC. | $42.58 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $36.03 | 2021 | |
| Neos Therapeutics, LP | $14.25 | 2021 | |
| Abbvie INC. | $13.56 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Hubbard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.